<DOC>
	<DOCNO>NCT00209261</DOCNO>
	<brief_summary>To evaluate preference subject Minirin® oral lyophilisate treatment compare Minirin® tablet treatment 6 week . To compare efficacy 2 formulation end 6-week treatment period use diary card data . To compare ease use formulation 3 6 week use VAS-scale . To validate PNE Quality Life ( QoL ) questionnaire . To evaluate safety . To compare compliance 2 formulation</brief_summary>
	<brief_title>A 6-week Open Label Cross-over Study With 2 Different Daily Doses Minirin® Oral Lyophilisate Children Adolescents With Primary Nocturnal Enuresis ( PNE )</brief_title>
	<detailed_description>To evaluate preference subject Minirin® oral lyophilisate treatment compare Minirin® tablet treatment 6 week . To compare efficacy 2 formulation end 6-week treatment period use diary card data . To compare ease use formulation 3 6 week use VAS-scale . To validate PNE Quality Life ( QoL ) questionnaire . To evaluate safety . To compare compliance 2 formulation</detailed_description>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Nocturnal Enuresis</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Children suffer primary nocturnal enuresis organic pathology . Children either sex , 5 15 year age ( 6 year The Netherlands France ) . Children minimum 6 wet night 2 week . Children previously treat desmopressin medication nocturnal enuresis enuresis alarm . Children receive substance know suspected potentiate antidiuretic hormone , e.g . SSRI , tricyclic antidepressant drug , chlorpromazine carbamazepine . Diagnosed renal diabetes insipidus central diabetes insipidus AVP ( arginine vasopressin ) deficiency . Proven urinary tract infection within past month document positive urine culture start study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>